Targeting APOBECs in cancer: It's about timing

Aaron N Hata; Mani Larijani

doi:10.1016/j.ccell.2024.03.010

Targeting APOBECs in cancer: It's about timing

Cancer Cell. 2024 Apr 8;42(4):497-501. doi: 10.1016/j.ccell.2024.03.010.

Authors

Aaron N Hata¹, Mani Larijani²

Affiliations

¹ Massachusetts General Hospital Cancer Center, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: ahata@mgh.harvard.edu.
² Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada. Electronic address: mani_larijani@sfu.ca.

PMID: 38593778
DOI: 10.1016/j.ccell.2024.03.010

Abstract

APOBEC3 cytidine deaminases have emerged as key drivers of mutagenesis in a wide spectrum of tumor types and are now appreciated to play a causal role in driving tumor evolution and drug resistance. As efforts to develop APOBEC3 inhibitors progress, understanding the timing and consequences of APOBEC3-mediated mutagenesis in distinct clinical contexts will be critical for guiding the development of anti-cancer therapeutic strategies.

MeSH terms

APOBEC Deaminases
Cytidine Deaminase / genetics
Humans
Mutagenesis
Neoplasms* / drug therapy
Neoplasms* / genetics

Substances

Cytidine Deaminase
APOBEC Deaminases